<DOC>
	<DOCNO>NCT02513147</DOCNO>
	<brief_summary>The purpose study ass change viral reservoir change IP/r dolutegravir HIV-1 infected patient maintain undetectable viral load Antiretroviral Therapy ( ART ) .</brief_summary>
	<brief_title>HIV Reservoir Dynamics After Switching Dolutegravir Patients PI 2 NRTI Based Regimen</brief_title>
	<detailed_description />
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<criteria>Adult patient infect HIV1 HIV RNA &lt; 50 copy / mL ≥ 1 year stable ART regimen ( ≥ 3 month ) base 2 NRTI PI ( Fosamprenavir , atazanavir , lopinavir darunavir ) boost 100 mg ritonavir , atazanavir ( 400 mg / ) boost ritonavir , 2 NRTIs abacavir + Lamivudine CD4 + lymphocytes &gt; 200 / mm3 Signature voluntary inform consent A woman may eligible enter participate study : 1 . No reproductive potentialdefined postmenopausal ( 12 month spontaneous amenorrhea ≥ 45 year age ) physically incapable get pregnant document tubal ligation , hysterectomy bilateral oophorectomy . 2 . It childbearing age negative pregnancy test day screen Day 1 agrees use one follow contraceptive method prevent pregnancy : Complete abstinence penisvaginal 2 week prior administration investigational product , throughout study , least 2 week discontinuation study drug ; Double barrier method ( male / spermicidal condom , male condom / diaphragm , diaphragm / spermicide ) ; Any intrauterine device ( IUD ) publish data show expected failure rate &lt; 1 % per year ( IUDs meet criterion ) Male sterilization confirm entry female subject study , man sexual partner woman Approved hormonal contraception Any method publish data show expect failure rate &lt; 1 % per year . Prior virologic failure integrase inhibitor Acquired Immune Deficiency Syndrome ( AIDS ) define illness last 48 week Glomerular filtration rate &lt; 50 mL / min , estimate Chronic Kidney Disease Epidemiology ( CKDEPI ) formula Alanine aminotransferase ( ALT ) ≥5 time Upper Limit Normal ( ULN ) ALT ≥3 X ULN total bilirubin ≥1,5 ULN ( &gt; 35 % direct bilirubin ) / unstable liver disease ( presence ascites , hepatic encephalopathy , hypoalbuminemia , esophageal varix persistent jaundice ) know biliary disorder exclude Gilbert syndrome asymptomatic lithiasis ) . Positive hepatitis B ( HBsAg + ) need Hepatitis C Virus ( HCV ) treatment study . Subjects severe hepatic impairment ( Child Pugh Class C ) . Patients unable understand study protocol condition investigator 's opinion could jeopardize compliance protocol Pregnant breastfeed History presence allergy study drug component</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>